Down in sympathy during after hours. The Juno clinical trials were conducted in conjunction with a unique chemotherapy regimen, This seems to be the focus of the death investigation. Juno is resubmiting test protocols to FDA to eliminate the non standard chemo regimen.
With the debt load ZBRA has taken on we can now expect that the familiar cycle of asset flipping will continue. What started with Symbol and went to Motorola and now ZBRA seems bound for Honeywell or GE at a steep discount.